Literature DB >> 27144862

Crizotinib Resensitization by Compound Mutation.

Alice T Shaw, Jeffrey A Engelman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27144862     DOI： 10.1056/NEJMc1601366

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  A crowded, but still varied, space: brigatinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer.

Authors:  Sawsan Rashdan; David E Gerber
Journal:  Transl Cancer Res       Date:  2017-02       Impact factor: 1.241

Review 2.  Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.

Authors:  Geeta Geeta Sharma; Ines Mota; Luca Mologni; Enrico Patrucco; Carlo Gambacorti-Passerini; Roberto Chiarle
Journal:  Cancers (Basel)       Date:  2018-02-28       Impact factor: 6.639

3.  An epigenetic switch regulates the ontogeny of AXL-positive/EGFR-TKi-resistant cells by modulating miR-335 expression.

Authors:  Polona Safaric Tepes; Debjani Pal; Trine Lindsted; Ingrid Ibarra; Amaia Lujambio; Vilma Jimenez Sabinina; Serif Senturk; Madison Miller; Navya Korimerla; Jiahao Huang; Lawrence Glassman; Paul Lee; David Zeltsman; Kevin Hyman; Michael Esposito; Gregory J Hannon; Raffaella Sordella
Journal:  Elife       Date:  2021-07-13       Impact factor: 8.713
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.